-
-
公开(公告)号：KR1020110044490A
公开(公告)日：2011-04-29
申请号：KR1020090101194
申请日：2009-10-23
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/495 , A61K35/28 , A61K38/00 , C12N5/0663 , C12N2501/15 , C12N2510/00 , A61K48/00 , C12N15/10 , A61K2300/00
Abstract: PURPOSE: A mesenchymsal stem cells and a composition containing the same for treating autoimmune diseases are provided to enhance autoantigen-specific CD4+ CD25+ Foxp3+ regulatory T cells and to treat autoimmune diseases. CONSTITUTION: A composition for treating autoimmune diseases contains mesenchymal stem cells in which TFG-beta-encoding nucleotide sequence is introduced and pharmaceutically acceptable carrier. The TGF-beta-encoding nucleotide sequence is sequence number 2. The TGF-beta-encoding nucleotide sequence is introduced by adenovirus-associated vector. The mesenchymal stem cell is derived from bone marrow-derived mesenchymal stem cells or adipose-derived mesenchymal stem cells.
Abstract translation: 目的：提供间充质干细胞和含有其的用于治疗自身免疫性疾病的组合物，以增强自身抗原特异性CD4 + CD25 + Foxp3 +调节性T细胞并治疗自身免疫性疾病。 构成：用于治疗自身免疫性疾病的组合物含有引入TFG-β编码核苷酸序列的间充质干细胞和药学上可接受的载体。 TGF-β编码核苷酸序列是序列号2.由腺病毒相关载体引入TGF-β编码的核苷酸序列。 间充质干细胞衍生自骨髓间充质干细胞或脂肪来源的间充质干细胞。
-
3.发明授权간엽줄기세포 및 면역조절 T 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 有权用于预防或治疗包含间充质干细胞和免疫调节性T细胞作为活性成分的免疫疾病的T细胞疗法组合物
公开(公告)号：KR101578591B1
公开(公告)日：2015-12-17
申请号：KR1020137021403
申请日：2012-02-17
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/28 , A61K31/21 , A61K35/17 , A61K39/001 , A61K2039/5158 , C12N5/0637 , C12N5/0667 , C12N2501/15 , C12N2501/51 , C12N2501/515 , A61K2300/00
Abstract: 본발명은간엽줄기세포및 면역조절 T 세포를유효성분으로포함하는면역질환의예방또는치료용세포치료제조성물에관한것이다. 본발명의세포치료제인간엽줄기세포와면역조절 T 세포를골수이식동물에게적용하는경우, 이식된골수가생착된후 숙주에대한거부반응이억제됨으로써면역질환, 예컨대이식편대숙주질환을감소시키는효과를갖는다. 또한이러한면역질환증상의감소수치는, 간엽줄기세포를단독을처리한경우와비교하여월등히향상된효과를가진다. 따라서상기와같은효과를갖는본 발명의세포치료제조성물은면역질환의예방또는치료에서유용하게사용될수 있다.
-
Patent Agency Ranking
公开(公告)号：KR101351121B1
公开(公告)日：2014-01-14
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
Abstract: 본 발명은 IL-27을 유효성분으로 포함하는 면역거부질환의 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명의 IL-27 단백질은 세포 또는 조직 이식 후 면역 거부 반응과 관련된 질환을 보이는 동물에게 투여하였을 때, 이식된 세포 또는 조직이 생착된 후 숙주에 대한 거부반응을 억제시킴으로써 면역거부질환을 완화시키는 효과를 갖는다. 따라서 상기와 같은 효과를 갖는 IL-27 단백질 및 IL-27 단백질을 암호화하는 핵산을 유효성분으로 포함하는 본 발명의 조성물은 면역 거부 반응 관련 질환의 예방 또는 치료에 유용하게 사용될 수 있는 특징이 있다.
-
5.发明公开간엽줄기세포 및 면역조절 Ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물 无效用于预防或治疗包含MESENCHYMAL STEM细胞和调节性T细胞的GRAFT-VERSUS-HOST疾病的细胞治疗组合物
公开(公告)号：KR1020120095022A
公开(公告)日：2012-08-28
申请号：KR1020110014398
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/28 , A61K31/21 , A61K35/17 , A61K39/001 , A61K2039/5158 , C12N5/0637 , C12N5/0667 , C12N2501/15 , C12N2501/51 , C12N2501/515 , A61K2300/00
Abstract: PURPOSE: A cell therapy composition for preventing or treating graft-versus-host diseases including immune-modulating T cells and mesenchymal stem cells is provided to control rejection against the host after transplanted marrow is engrafted, thereby reducing the generation of the graft-versus-host diseases. CONSTITUTION: A cell therapy composition for preventing or treating graft-versus-host diseases includes immune-modulating T cells and mesenchymal stem cells. The mesenchymal stem cell is a human derivative mesenchymal stem cell. The immune-modulating T cell is an immune-modulating T cell which is induced by retinal. The immune-modulated T cell is CD4+CD25+ immune-modulated T cell which is induced by processing retinal, anti-CD3, TGF-b, and anti-CD28 on the CD4+ T cell. The composition includes 1×10^4 cell/kg-1×10^8 cell/kg of the Cell Therapy Products.
Abstract translation: 目的：提供用于预防或治疗移植物抗宿主病，包括免疫调节性T细胞和间充质干细胞的细胞治疗组合物，用于在移植骨髓后控制对宿主的排斥反应，从而减少移植物抗宿主病的产生， 宿主病。 构成：用于预防或治疗移植物抗宿主病的细胞治疗组合物包括免疫调节T细胞和间充质干细胞。 间充质干细胞是人类衍生的间充质干细胞。 免疫调节性T细胞是由视网膜诱导的免疫调节性T细胞。 免疫调节的T细胞是通过在CD4 + T细胞上处理视网膜，抗CD3，TGF-b和抗CD28诱导的CD4 + CD25 +免疫调节的T细胞。 该组合物包括1×10 ^ 4细胞/ kg-1×10 ^ 8细胞/ kg的细胞治疗产品。
-
6.发明公开간엽줄기세포 및 면역조절 T 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 有权用于预防或治疗包含MESENCHYMAL STEM细胞和调节性T细胞的免疫疾病的细胞治疗组合物
公开(公告)号：KR1020140040696A
公开(公告)日：2014-04-03
申请号：KR1020137021403
申请日：2012-02-17
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/28 , A61K31/21 , A61K35/17 , A61K39/001 , A61K2039/5158 , C12N5/0637 , C12N5/0667 , C12N2501/15 , C12N2501/51 , C12N2501/515 , A61K2300/00
Abstract: The present invention relates to a cell therapy composition for preventing or treating immune diseases comprising mesenchymal stem cells and immunoregulatory T-cells as active ingredients. By infusing the mesenchymal stem cells and the immunoregulatory T-cells, which are cellular therapeutic agents of the present invention, into bone marrow transplanted animals, rejection to a host is suppressed after an engraftment of the transplanted bone marrow, thereby obtaining an effect of reducing immune diseases, such as graft-versus-host disease (GVHD). Moreover, the effect of such GVHD reduction is significantly greater than that of a reduction level obtained from a sole infusion of mesenchymal stem cells. Accordingly, the cell therapy composition of the present invention having such effects can be useful in the prevention or treatment of immune diseases. [Reference numerals] (AA) First experimental group; (BB) Second experimental group; (CC) Control group
Abstract translation: 本发明涉及用于预防或治疗包含间充质干细胞和免疫调节性T细胞作为活性成分的免疫疾病的细胞治疗组合物。 通过将作为本发明的细胞治疗剂的间充质干细胞和免疫调节性T细胞注入骨髓移植动物中，移植移植的骨髓被移植后抑制宿主的排斥，从而获得降低 免疫疾病，如移植物抗宿主病（GVHD）。 此外，这种GVHD降低的效果显着大于从单次输注间充质干细胞获得的还原水平的效果。 因此，具有这种效果的本发明的细胞治疗组合物可用于预防或治疗免疫疾病。 （附图标记）（AA）第一实验组; （BB）第二实验组; （CC）对照组
-
公开(公告)号：KR101301262B1
公开(公告)日：2013-08-27
申请号：KR1020090101194
申请日：2009-10-23
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/495 , A61K35/28 , A61K38/00 , C12N5/0663 , C12N2501/15 , C12N2510/00 , A61K2300/00
Abstract: 본 발명의 하나이상의 구체예는 TGFβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도를 제공한다.
간엽줄기세포, 자가면역질환, CD4+CD25+ Foxp3 조절성 T 세포, Th17-
公开(公告)号：KR1020120095046A
公开(公告)日：2012-08-28
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/20 , A61K48/005 , Y10S424/81
Abstract: PURPOSE: A composition for preventing or treating immunological rejection diseases including IL-27 is provided to alleviate the immunological rejection disease by suppressing rejection towards the host after the transplanted cell or organ is engrafted. CONSTITUTION: A composition for preventing or treating immunological rejection diseases includes IL-27 as an active component. The IL-27 has amino acid sequence described in the sequence number 1(SEQ ID NO:1). The composition for preventing or treating immunological rejection diseases includes a vector containing polynucleotide which codes the IL-27 as an active ingredient. The polynucleotide has the base sequence described in the sequence number 2. The immunological rejection disease is graft-versus-host disease.
Abstract translation: 目的：提供一种用于预防或治疗免疫排斥疾病（包括IL-27）的组合物，用于通过在移植的细胞或器官移植后抑制对宿主的排斥来减轻免疫排斥疾病。 构成：用于预防或治疗免疫排斥疾病的组合物包括IL-27作为活性成分。 IL-27具有序列号1（SEQ ID NO：1）中描述的氨基酸序列。 用于预防或治疗免疫排斥疾病的组合物包括编码IL-27作为活性成分的含有多核苷酸的载体。 多核苷酸具有序列号2中描述的碱基序列。免疫排斥疾病是移植物抗宿主病。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.027 seconds)
